<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02013479</url>
  </required_header>
  <id_info>
    <org_study_id>DK-CATALYST</org_study_id>
    <nct_id>NCT02013479</nct_id>
  </id_info>
  <brief_title>Selenium Supplementation in Autoimmune Thyroiditis</brief_title>
  <acronym>CATALYST</acronym>
  <official_title>The Chronic Autoimmune Thyroiditis Quality Of Life Selenium Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steen Bonnema</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital of South West Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pharma Nord</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Danish Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Region of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Southern Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Odense University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our aim is to investigate if selenium supplementation versus placebo adjuvant to the standard
      treatment with levothyroxine (LT4) in patients with autoimmune thyroiditis will lead to
      improved thyroid specific quality of life, and reduced autoimmune activity. The trial will
      include 472 participants (2 X 236) from four clinical trial sites.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Chronic autoimmune thyroiditis (AIT) is a common autoimmune disease that often
      leads to impaired function of the thyroid gland, increases in incidence with age, and has an
      8-9 time female preponderance. Quality of life is often impaired and complaints persist in a
      considerable number of patients, even after restoration of euthyroidism. The autoimmune
      component of the disease has been suggested as an explanation for this. Selenium is a micro
      nutritive essential for human health and the thyroid gland has the highest selenium
      concentration of all human tissues. Selenoproteins catalyse thyroid hormone metabolism and
      anti-oxidative processes in thyrocytes. In addition they are important to immune function. In
      Denmark, patients with AIT have lower blood selenium concentration than the background
      population. The majority of 13 randomised trials have shown that selenium supplementation
      decreases serum thyroid peroxidase antibody levels (TPO-Ab) in patients with AIT, when
      compared with placebo. We hypothesise that adjuvant selenium may be beneficial in the
      treatment of AIT.

      Objectives: To investigate if selenium supplementation versus placebo adjuvant to the
      standard treatment with levothyroxine (LT4) in patients with AIT will lead to improved
      thyroid specific quality of life, and reduced autoimmune activity.

      Design and trial size: The CATALYST trial is an investigator-initiated randomised, blinded,
      multicentre clinical trial of selenium supplementation versus placebo in patients with AIT.
      The trial will include 472 participants (2 X 236) from four clinical trial sites.

      Intervention and duration: The experimental intervention group will receive 200 μg
      selenium-enriched yeast as two oral tablets once daily for 12 months. The control group will
      receive two placebo tablets, identical in appearance, taste and smell, once daily for 12
      months. Six months additional follow-up leads to a trial duration of 18 months. The
      experimental supplement will be SelenoPrecise® by Pharma Nord ApS.

      Time schedule: July 2012 - February 2014: preparation, approval and trial registration .
      March 2014: first participant first visit. March 2016: last participant first visit.
      September 2017: last participant last visit. Autumn 2017: analysis of biological samples and
      data, preparation of manuscripts.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Thyroid related quality of life</measure>
    <time_frame>12 months after initation of intervention</time_frame>
    <description>Measured in composite score based on the ThyPRO questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Thyroid peroxidase antibody concentration (TPO-Ab)</measure>
    <time_frame>12 months after initation of intervention</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Levothyroxine (LT4) dosage</measure>
    <time_frame>12 months after initation of intervention</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">472</enrollment>
  <condition>Autoimmune Thyroiditis</condition>
  <arm_group>
    <arm_group_label>SelenoPRECISE</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>SelenoPRECISE</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>SelenoPRECISE</intervention_name>
    <description>Produced by Pharma Nord ApS, Vejle, Denmark</description>
    <arm_group_label>SelenoPRECISE</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Produced by Pharma Nord ApS, Vejle, Denmark</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥18 years.

          2. Serum-TPO-Ab ≥ 100 IU/mL measured within the last 12 months.

          3. Receiving LT4 treatment.

             - Serum-TSH ≥ 4.0 mU/L measured prior to treatment initiation

          4. Written informed consent.

        Exclusion Criteria:

          1. Previous diagnosis of toxic nodular goitre, Graves' hyperthyroidism, post-partum
             thyroiditis or thyroid associated orbitopathy (TAO).

          2. Previous radioiodine therapy, anti-thyroid treatment or thyroid surgery.

          3. Previous diagnosis of non-melanoma skin cancer.

          4. Morbidity, rendering the participant unable to process patient reported outcomes or
             receive intervention during the trial.

          5. Systemic immunomodulatory medication.

          6. Other medication known to affect thyroid function.

          7. Pregnancy, breastfeeding, or planned pregnancy within 18 months.

          8. Allergy towards the components in the selenium or placebo pills.

          9. Intake of selenium supplementation ≥ 55 μg/d.

         10. Unable to read or understand Danish.

         11. Lack of informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steen J Bonnema, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Laszlo Hegedüs, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kristian H Winther, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Odense University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Torquil Watt, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Per Cramon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulla Feldt-Rasmussen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Åse K Rasmussen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jeppe Gram, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital of South West Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nils J Knudsen, MD, DMSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bispebjerg Hospital, Denmark</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steen J Bonnema, MD, DMSc</last_name>
    <phone>004565413437</phone>
    <email>steen.bonnema@rsyd.dk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristian H Winther, MD</last_name>
    <phone>004561713854</phone>
    <email>kristian.winther@rsyd.dk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clinic of Medical Endocrinology, Copenhagen University Hospital, Rigshospitalet</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Endocrinology and Gastroenterology, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Internal Medicine, Hospital of South West Denmark</name>
      <address>
        <city>Esbjerg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Department of Endorcrinology and Metabolism, Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 3, 2013</study_first_submitted>
  <study_first_submitted_qc>December 11, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 17, 2013</study_first_posted>
  <last_update_submitted>June 6, 2016</last_update_submitted>
  <last_update_submitted_qc>June 6, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Odense University Hospital</investigator_affiliation>
    <investigator_full_name>Steen Bonnema</investigator_full_name>
    <investigator_title>Chief Physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thyroiditis</mesh_term>
    <mesh_term>Thyroiditis, Autoimmune</mesh_term>
    <mesh_term>Hashimoto Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

